{
    "pmcid": "10938001",
    "qa_pairs": {
        "How does the JN.1 lineage's affinity for the ACE2 receptor compare to that of BA.2.86.1?": [
            "JN.1 shows a decreased affinity for the ACE2 receptor",
            "JN.1 shows an increased affinity for the ACE2 receptor",
            "JN.1 shows the same affinity for the ACE2 receptor",
            "JN.1 shows no affinity for the ACE2 receptor"
        ],
        "What is a key mutation in the JN.1 lineage that contributes to its enhanced immune evasion capabilities?": [
            "F455S substitution in the spike protein",
            "D614G substitution in the spike protein",
            "N501Y substitution in the spike protein",
            "E484K substitution in the spike protein"
        ],
        "What is the primary reason for JN.1's success compared to BA.2.86.1?": [
            "Enhanced immune evasion",
            "Higher replication efficiency",
            "Increased ACE2 receptor binding",
            "Greater transmission rate"
        ],
        "What should nanobody designs focus on to combat the high immune evasion properties of JN.1?": [
            "Targeting conserved regions of the spike protein",
            "Increasing affinity for the ACE2 receptor",
            "Enhancing viral replication",
            "Reducing viral load in nasal epithelial cells"
        ],
        "What type of studies are recommended to assess the broad-spectrum efficacy of nanobodies against JN.1 and other variants?": [
            "Cross-Neutralization Studies",
            "Viral Load Reduction Studies",
            "ACE2 Binding Affinity Studies",
            "Replication Efficiency Studies"
        ]
    }
}